EGFR and non-small cell lung carcinoma: Moreover, clinical studies reported that treatment of selective EGFR TKIs as monotherapy, including gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva), leads to tumor regression in 12–27% of advanced NSCLC patients [1], [2], [3].